Comparative Pharmacology
Head-to-head clinical analysis: QVAR REDIHALER versus VANCERIL DOUBLE STRENGTH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QVAR REDIHALER versus VANCERIL DOUBLE STRENGTH.
QVAR REDIHALER vs VANCERIL DOUBLE STRENGTH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beclomethasone dipropionate is a prodrug that is hydrolyzed by esterases to the active metabolite beclomethasone-17-monopropionate (17-BMP). 17-BMP is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to modulation of gene expression involved in inflammatory pathways, including inhibition of pro-inflammatory cytokines, reduction of eosinophil survival and migration, and suppression of mast cell mediators.
Beclomethasone dipropionate is a corticosteroid with anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduced arachidonic acid release, and decreased synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production, adhesion molecule expression, and eosinophil survival, thereby reducing airway inflammation.
Inhalation: 40-80 mcg twice daily; maximum 320 mcg twice daily.
2 inhalations (168 mcg beclomethasone dipropionate) twice daily via oral inhalation.
None Documented
None Documented
1.5-2.0 hours (terminal half-life) after inhalation; supports twice-daily dosing.
Terminal elimination half-life: 1.5–2 hours for beclomethasone dipropionate; 2.7 hours for active metabolite beclomethasone-17-monopropionate. Clinical context: supports twice-daily dosing.
Primarily hepatic metabolism via CYP3A4; metabolites are excreted in feces (~64%) and urine (~12%).
Primarily hepatic metabolism; metabolites excreted renally (~90% as free and conjugated metabolites) and fecally (<10%).
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid